Findings

What do systematic reviews say?

238 questions · 242 findings · 21 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 37 · 15.3%GRADE not reported 15 · 6.2%Very low 78 · 32.2%Low 52 · 21.5%Moderate 49 · 20.2%High 11 · 4.5%

Atypical vs atypical antipsychotics (only short term)

No improvement (clozapine vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
High

Atypical vs atypical antipsychotics (only short term)

Use of other antipsychotics · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Moderate

Atypical vs atypical antipsychotics (only short term)

Drug‐induced diabetes (clozapine vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Moderate

Atypical vs atypical antipsychotics (only short term)

Elevated prolactin (risperidone vs quetiapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

Atypical vs atypical antipsychotics (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
High

Atypical vs atypical antipsychotics (only short term)

Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Atypical vs atypical antipsychotics (only short term)

No improvement (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Moderate

Atypical vs typical antipsychotics (only short term)

Worse or no improvement · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Low

Atypical vs typical antipsychotics (only short term)

Adverse effects ‐ anticholinergic effects · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Atypical vs typical antipsychotics (only short term)

Drop in the absolute neutrophil count below 1500 per mm3 · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical vs typical antipsychotics (only short term)

Adverse effects: Leaving the study early · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Moderate

Atypical vs Typical antipsychotics

Diabetes · Adults with mental disorders in low‐ and middle‐income countries

Atypical showed no clear difference in diabetes (ADA criteria) (6 weeks) compared with typical antipsychotic medications (low certainty).

1 finding from 1 review

Interventions for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries 2021 · Cochrane Headline outcomes only
RR 0.5 [0.03, 7.73]
1 study · 93 participants
Low

Atypical vs Typical antipsychotics

Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries

Atypical showed no clear difference in drop‐outs (6 to 54 weeks) compared with typical antipsychotic medications (low certainty).

1 finding from 1 review

Interventions for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries 2021 · Cochrane Headline outcomes only
RR 1.31 [0.63, 2.69]
2 studies · 144 participants
Low

Atypical vs Typical antipsychotics

Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries

1 finding from 1 review

Interventions for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 211 participants
Moderate

Atypical vs Typical antipsychotics

Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries

1 finding from 1 review

Interventions for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 141 participants
Moderate

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

No response · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 255 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Symptomatic hyperprolactinaemia · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Use of antiparkinsonian medications · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical antipsychotics vs placebo (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Moderate